Ausgabe 5/2020
Inhalt (18 Artikel)
Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma
Colby S. Shemesh, Priya Agarwal, Tong Lu, Calvin Lee, Randall C. Dere, Xiaobin Li, Chunze Li, Jin Y. Jin, Sandhya Girish, Dale Miles, Dan Lu
Evaluating the immunoproteasome as a potential therapeutic target in cisplatin-resistant small cell and non-small cell lung cancer
Tetsuaki Shoji, Eiki Kikuchi, Junko Kikuchi, Yuta Takashima, Megumi Furuta, Hirofumi Takahashi, Kosuke Tsuji, Makie Maeda, Ichiro Kinoshita, Hirotoshi Dosaka-Akita, Jun Sakakibara-Konishi, Satoshi Konno
Phase 1 study of napabucasin, a cancer stemness inhibitor, in patients with advanced solid tumors
Akihito Kawazoe, Yasutoshi Kuboki, Hideaki Bando, Shota Fukuoka, Takashi Kojima, Yoichi Naito, Shuichi Iino, Yasuhide Yodo, Toshihiko Doi, Kohei Shitara, Takayuki Yoshino
Docetaxel dose-intensity effect on overall survival in patients with metastatic castrate-sensitive prostate cancer
Igal Kushnir, Ranjeeta Mallick, Michael Ong, Christina Canil, Dominick Bossé, Kim Koczka, Neil M. Reaume
Assessment of pharmacokinetic variations of capecitabine after multiple administration in rats: a physiologically based pharmacokinetic model
Shuhei Sakai, Shinji Kobuchi, Yukako Ito, Toshiyuki Sakaeda
Pharmacokinetics and pharmacogenetics of high-dose methotrexate in Chinese adult patients with non-Hodgkin lymphoma: a population analysis
Lin Yang, Hui Wu, Brenda C. M. de Winter, Chang-cheng Sheng, Hong-qiang Qiu, Yu Cheng, Juan Chen, Qiu-ling Zhao, Jing Huang, Zheng Jiao, Rui-xiang Xie
Effects of repeated oral doses of ketoconazole on a sequential ascending single oral dose of fedratinib in healthy subjects
Ken Ogasawara, Christine Xu, Vanaja Kanamaluru, Maria Palmisano, Gopal Krishna
A phase I study investigation of metabolism, and disposition of [14C]-anlotinib after an oral administration in patients with advanced refractory solid tumors
Yiqian Liu, Lianke Liu, Lingxiang Liu, Tongshan Wang, Lian Guo, Yixiang Wang, Zhengzhen Gao, Yongqian Shu
Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer
Sanne C. F. A. Huijberts, Robin M. J. M. van Geel, Emilie M. J. van Brummelen, Frans L. Opdam, Serena Marchetti, Neeltje Steeghs, Saskia Pulleman, Bas Thijssen, Hilde Rosing, Kim Monkhorst, Alwin D. R. Huitema, Jos H. Beijnen, René Bernards, Jan H. M. Schellens
Sorafenib administered using a high-dose, pulsatile regimen in patients with advanced solid malignancies: a phase I exposure escalation study
L. H. Mammatas, A. S. Zandvliet, M. Rovithi, R. J. Honeywell, E. L. Swart, G. J. Peters, C. W. Menke-van der Houven van Oordt, H. M. W. Verheul
Rapid decrease in serum VEGF-A levels may be a worse prognostic biomarker for patients with platinum-resistant recurrent ovarian cancer treated with bevacizumab and gemcitabine
Hiroaki Soyama, Morikazu Miyamoto, Hiroko Matsuura, Hideki Iwahashi, Soichiro Kakimoto, Hiroki Ishibashi, Takahiro Sakamoto, Taira Hada, Jin Suminokura, Masashi Takano
Inhibition of cyclin-dependent kinases by AT7519 enhances nasopharyngeal carcinoma cell response to chemotherapy
Xin Wei, Jiabin Nian, Jing Zheng, Yangli He, Min Zeng
Clinical pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematologic malignancies with an IDH1 mutation
Bin Fan, David Dai, Courtney D. DiNardo, Eytan Stein, Stéphane de Botton, Eyal C. Attar, Hua Liu, Guowen Liu, Ian Lemieux, Samuel V. Agresta, Hua Yang
The influence of PD-L1 genetic variation on the prognosis of R0 resection colorectal cancer patients received capecitabine-based adjuvant chemotherapy: a long-term follow-up, real-world retrospective study
Jinsong Su, Baiyun Dai, Weitang Yuan, Guixian Wang, Zhiyong Zhang, Zhen Li, Jinbo Liu, Junmin Song
Intravenous 5-fluoro-2′-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors
Geraldine O.’Sullivan Coyne, Lihua Wang, Jennifer Zlott, Lamin Juwara, Joseph M. Covey, Jan H. Beumer, Mihaela C. Cristea, Edward M. Newman, Stephen Koehler, Jorge J. Nieva, Agustin A. Garcia, David R. Gandara, Brandon Miller, Sonny Khin, Sarah B. Miller, Seth M. Steinberg, Larry Rubinstein, Ralph E. Parchment, Robert J. Kinders, Richard L. Piekarz, Shivaani Kummar, Alice P. Chen, James H. Doroshow
A phase I study of the effect of repeated oral doses of pantoprazole on the pharmacokinetics of a single dose of fedratinib in healthy male subjects
Ken Ogasawara, Bradley Vince, Christine Xu, Meng Zhang, Maria Palmisano, Gopal Krishna
Cerebrospinal fluid penetration of the colony-stimulating factor-1 receptor (CSF-1R) inhibitor, pexidartinib
Priya S. Shankarappa, Cody J. Peer, Arman Odabas, Cynthia L. McCully, Rafael C. Garcia, William D. Figg, Katherine E. Warren
Correction to: Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer
Hani M. Babiker, Mohammed Milhem, Joseph Aisner, William Edenfield, Dale Shepard, Michael Savona, Swaminathan Iyer, Maen Abdelrahim, C. L. Beach, Barry Skikne, Eric Laille, Kao-Tai Tsai, Thai Ho